Amniotic Fluid Tandem Mass Spectrometry for Pregnancies Complicated by NIH and Severe Symmetrical IUGR (TandemMS)
Amniotic Fluid Tandem Mass Spectrometry for Pregnancies Complicated by Nonimmune Hydrops and Severe Symmetrical Intrauterine Growth Restriction-A Multicenter Prospective Pilot Cohort Study
Sponsor: Obstetrix Medical Group
Terminated
No metabolic disordered ID'd by TMS in either control/test group at \>50%enrolled
Other terminated trials from Obstetrix Medical Group
More terminations from Obstetrix Medical Group
Other Fetal Growth Retardation trials with similar outcome
Listed as NCT00143039, this observational or N/A phase trial focuses on Fetal Growth Retardation and Hydrops Fetalis and remains terminated or withdrawn. Sponsored by Obstetrix Medical Group, it has been updated 8 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Feb 2023 — Jul 2024 [monthly]
Terminated
-
Jan 2021 — Feb 2023 [monthly]
Terminated
-
Jun 2018 — Jan 2021 [monthly]
Terminated
▶ Show 3 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Terminated
Phase: PHASE1 → None
-
Feb 2018 — Apr 2018 [monthly]
Terminated PHASE1
-
Jan 2017 — Feb 2018 [monthly]
Terminated PHASE1
First recorded
Mar 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Obstetrix Medical Group
For direct contact, visit the study record on ClinicalTrials.gov .